Clark Kent, can you evaluate this bexmarilimab development from the perspective of how much data competing actors would get for their own development work if all published data were truly detailed, almost perfect? I’m thinking about this from a different educational background. Generally, there’s no reason to publish overly detailed information about a product under development before it’s brought to market. Based on visible results (e.g., tire comparison), the product is simply better, and thus sales are made. And those details (of the compound, etc.) are not published.
15 Likes